Skip to main navigation

>> Site Menu

  • Our Company
  • Our Science
    • ABCD Platform
    • Scientific Presentations
  • Focus Areas
    • Wet Age Related Macular Degeneration
    • Diabetic Eye Disease
    • Retinal Vein Occlusion
    • Macular Edema Secondary to Inflammation (MESI)
  • Our Pipeline
    • Tarcocimab Tedromer
    • KSI-501
    • KSI-101
  • Our Culture
    • Join the Team
  • INVESTORS & MEDIA
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • ESG Report
    • Investor Resources
Kodiak Sciences

>> Site Menu

  • Our Company
  • Our Science
    • ABCD Platform
    • Scientific Presentations
  • Focus Areas
    • Wet Age Related Macular Degeneration
    • Diabetic Eye Disease
    • Retinal Vein Occlusion
    • Macular Edema Secondary to Inflammation (MESI)
  • Our Pipeline
    • Tarcocimab Tedromer
    • KSI-501
    • KSI-101
  • Our Culture
    • Join the Team
  • INVESTORS & MEDIA
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • ESG Report
    • Investor Resources

Annual Reports

> Financial Info - Sub Nav

  • SEC Filings
  • Quarterly Results
  • Annual Reports

Annual Reports

2024 Annual Report and Shareholder Letter

2024 AR

 

2024 Annual Report and Shareholder Letter

 

Click here to view/download

 

Listen to the annual meeting recording here

 

Date Title Documents
May 20, 2021
2020 Annual Report and Shareholder Letter
Click here to view/download: 4.5 MB
April 29, 2020
2019 Annual Report and Shareholder Letter
Click here to view/download: 3.2 MB
April 25, 2019
2018 Annual Report and Shareholder Letter
Click here to view/download: 2.5 MB

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
 
 
 
Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1250 Page Mill Rd
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter
Copyright © 2026 Kodiak Sciences Inc.